Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Oncimmune Holdings PLC - Nottingham-based immunodiagnostics developer - Signs follow-on contract with unnamed US research organisation to validate findings from prior study to assess the autoimmune response to Covid-19 infection.
New samples will be analysed using the SeroTag Covid-19 autoantigen assay.
‘We have now successfully completed four studies for this world-leading medical research organisation relating to Covid-19. This latest additional contract, utilising Oncimmune's validated infectious diseases panel, will proceed to validate the findings from our prior contract. This follow-on contract and others we have announced underlines Oncimmune's leading position in autoimmune profiling of infectious disease,’ said Chief Executive Officer Adam Hill.
Current stock price: 132.33 pence, up 3.8%
12-month change: down 35%
Copyright 2022 Alliance News Limited. All Rights Reserved.